ClinicalTrials.gg
Status unknownNCT00294996Updated Mar 31, 2009

Trial of Myocet in Metastatic Breast Cancer

A Phase 3 interventional study of Myocet in Breast Cancer, sponsored by Sopherion Therapeutics. Status unknown at 105 sites in 11 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-31.

Sponsored by Sopherion Therapeutics · Phase 3, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Mar 2009), so the status shown — last known as Active, not recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
363
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 197 studies testing doxorubicin in Breast Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Doxorubicin · Breast Neoplasms.

Enrollment
20th of 189
363 · median 56
Started
2006
with 18 others
Phase 3
28 of 197
3 open now
Registered
64th of 197
by date

Among the 197 studies testing doxorubicin in Breast Neoplasms, this one is the 20th largest by enrollment of the 189 interventional ones that give a count, is one of 19 that started in 2006, is one of 28 in phase 3, and was the 64th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

9 of the 197 studies testing doxorubicin in Breast Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About doxorubicin

Doxorubicin: first FDA approval 1974 (DOXORUBICIN HYDROCHLORIDE), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 197 studies testing doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of the study is to examine the safety and effectiveness of the drug combination of Myocet, paclitaxel and trastuzumab compared to paclitaxel and trastuzumab without Myocet, as first line treatment for patients with metastatic HER2+ breast cancer.

03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Metastatic Her2+ Breast cancer
  • Myocet
  • liposomal doxorubicin
  • trastuzumab
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Her2+ Breast cancer by FISH analysis
  • No prior chemotherapy for metastatic disease
  • normal

Exclusion criteria

Exclusion Criteria:

  • prior doxorubicin treatment exceeding 300 mg/m2 or epirubicin exceeding 600 mg/m2
  • relapse within 12 months of completion of adjuvant trastuzumab, taxane or anthracycline therapy
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
363 participants (actual)

Interventions

This study also gives Trastuzumab. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival

Secondary outcomes

  1. Overall Survival

  2. Safety

07

Study locations

105 sites
  • Scripps Cancer Center Clinical Research
    San Diego, California 92121, United States
  • University of Colorado
    Aurora, Colorado 80045, United States
  • Northwest Hematology/Oncology Associates
    Coral Springs, Florida 33065, United States
  • Osceola Cancer Center
    Kissimmee, Florida 34741, United States
  • UM/Sylvester Cancer Center
    Plantation, Florida 33324, United States
  • John B. Amos Cancer Center
    Columbus, Georgia 31904, United States
  • Clintell, Inc
    Skokie, Illinois 60076, United States
  • Hutchinson Clinic P.A.
    Hutchinson, Kansas 67502, United States
  • Western Maryland Health System
    Cumberland, Maryland 21502, United States
  • Brody School of Medicine @ ECU
    Greenville, North Carolina 27834, United States
  • Aultman Hospital Cancer Center
    Canton, Ohio 44710, United States
  • Hematology Oncology Consultants, Inc.
    Columbus, Ohio 43235, United States
  • Vita Hematology Oncology
    Bethlehem, Pennsylvania 18015, United States
  • Hematology & Oncology Associates of NEPA
    Dunmore, Pennsylvania 18512, United States
  • PA Oncology Hematology Asso
    Philadelphia, Pennsylvania 19106, United States
  • M. Francisco Gonzalez
    Columbia, South Carolina 29203, United States
  • Sioux Valley Clinic
    Sioux Falls, South Dakota 57104, United States
  • Tennessee Cancer Specialists
    Knoxville, Tennessee 37920, United States
  • Centro Oncologico de Excelencia
    Buenos Aires, Argentina
  • Hospital Enrique Tornú
    Buenos Aires, Argentina
  • Hospital Interzonal Gral de Agudos " EVITA"
    Buenos Aires, Argentina
  • Hospital Profesor A. Posadas
    Buenos Aires, Argentina
  • Santorio Municipal Dr. J. Mendez
    Buenos Aires, Argentina
  • Unidad Oncologica del Neuquen
    Neuquen, Argentina
  • CAICI Instituto
    Santa Fe, Argentina
  • Centro Oncologico Rosario
    Santa Fe, Argentina
  • ISIS Clinica Especializada
    Santa Fe, Argentina
  • Ceten
    Villa Dominico, Argentina
  • Dr. Leon Richard Oncology Centre
    Moncton, New Brunswick E1C 8X3, Canada
  • QEII Health Sciences Centre
    Halifax, Nova Scotia B3H 1V7, Canada
  • London Regional Cancer Centre/London Health Science Centre
    London, Ontario N6A 4L6, Canada
  • The Ottawa Hospital Regional Cancer Center
    Ottawa, Ontario K1H 8L6, Canada
  • Princess Margaret Hospital
    Toronto, Ontario M5G 2M9, Canada
  • CHUM Hospital Notre-Dame
    Montreal, Quebec H2L 4M1, Canada
  • McGill University
    Montreal, Quebec H2W 1S6, Canada
  • Allan Blair Cancer Centre
    Regina, Saskatchewan S47 7T1, Canada
  • Saskatoon Cancer Centre
    Saskatoon, Saskatchewan S7N 4H4, Canada
  • Hopital du St. Sacrement
    Quebec, G1S 4L8, Canada
  • U.K Charité, Campus Mitte
    Berlin, Germany
  • Universitätsklinikum Magdeburg
    Magdeburg, Germany
  • Gemeinschaftspraxis Gynäkologie & Geburtshilfe
    Mannheim, Germany
  • Frauenklinik von Roten Kreuz
    München, Germany
  • Klinikum Offenbach
    Offenbach, Germany
  • Üniversitäts Klinikum Tübingen
    Tübingen, Germany
  • Dr. Horst Schmidt Kliniken
    Wiesbaden, Germany
  • Gujarat Cancer Research Institute
    Asarwa, Gujarat, India
  • Kidwai Memorial Institute of Oncology
    Bangalore, India
  • Manipal Hospital
    Bangalore, India
  • Apollo Specialty Hospitals, Chennai
    Chennai, India
  • Nizam's Institute of Medical Science
    Hyderabaad, India
  • SMSMedicalCollegeHospital,
    Jaipur, India
  • Lakeshore Hospital and Research Centre Ltd
    Kerala, India
  • Himadri cancer welfare trusr
    Kolkata, India
  • Orchid Nursing Home,
    Kolkata, India
  • Ruby Hall Clinic
    Maharashtra, India
  • Tata Memorial Hospital
    Maharashtra, India
  • Kasturba Medical College,
    Mangalore, India
  • Jaslok Hospital and Research Centre
    Mumbai, India
  • Batra Hospital & Medical Research Center
    New Delhi, India
  • Indraprastha Apollo Hospitals
    New Delhi, India
  • Safdarjung Hospital & Vardhaman Mahaveer Medical College
    New Delhi, India
  • Fortis Hospital
    Noida, India
  • Azienda Ospedialera Pugliese-Ciaccio
    Catanzaro, Italy
  • Clinica Oncologica Ospedale
    Chieti, Italy
  • DIMI - Università di Genova
    Genova, Italy
  • ARNAS CIVICO. Presidio Ospedaliero M. Ascoli
    Palermo, Italy
  • Oncologia Medica
    Pavia, Italy
  • Day Hospital Oncologico,
    Roma, Italy
  • Istituto Clinico Humanitas
    Rozzano, Italy
  • SP SK nr1 ACK AMG
    Gdańsk, Poland
  • Centrum Onkologii - Instytut Marii Skłodowskiej-Curie Oddział Gliwice
    Gliwice, Poland
  • Samodzielny Publiczny Szpital
    Lublin, Poland
  • Zakład Opieki Zdrowotnej MSWiA
    Olsztyn, Poland
  • Szpital Wojewódzki im. Św. Łukasza
    Tarnow, Poland
  • Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie
    Warszawa, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, Poland
  • SP ZOZ Szpital Wojewódzki
    Zielona Gora, Poland
  • Regionalny Ośrodek Onkologiczny
    Łódź, Poland
  • Regionalny Szpital Specjalistyczny
    Świdnica, Poland
  • nstituto Português de Oncologia Francisco Gentil
    Lisbon, Portugal
  • Non-state Health Care Insitution "N.A. Semashko Central Clinical Hospital #2" of the "Russian Railways" Joint Stock Company
    Moscow, Russian Federation
  • State Institution "N.N. Blokhin Russian Oncology Scientific Center" of the Russian Academy of Medical Sciences
    Moscow, Russian Federation
  • State Science Institution "P.A. Hertzen Moscow Oncology Research Institute" of the Federal Agency of Health Care and Social Development
    Moscow, Russian Federation
  • State Health Care Institution "Regional Clinical Oncology Dispensary"
    Ryazan, Russian Federation
  • Municipal Health Care Institution of the City of Sochi "Oncology Dispensary"
    Sochi, Russian Federation
  • St. Petersburg State Health Care Institution "City Clinical Oncology Dispensary"
    St Petersberg, Russian Federation
  • State Science Institution "Prof. N.N. Petrov Research Institute of Oncology" of the Federal Agency of Health Care and Social Development
    St Petersberg, Russian Federation
  • Research Institute of Pulmonology affiliated with State Educational Institution "St. Petersburg State Medical University n.a. academician I.P. Pavlov" of the Federal Agency of Health Care and Social Development
    St. Petersberg, Russian Federation
  • State Health Care Institution "Leningrad Regional Oncology Dispensary"
    St. Petersburg, Russian Federation
  • State Health Care Institution of the Yaroslavl Region "Yaroslavl Regional Oncology Dispensary"
    Yaroslavl, Russian Federation
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida
    Lleida, Spain
  • Hospital 12 de Octubre
    Madrid, Spain
  • Hospital Son Dureta
    Palma de Mallorca, Spain
  • Hospital Clínico Universitario de Salamanca
    Salamanca, Spain
  • Hospital Virgen Macarena
    Sevilla, Spain
  • Hospital Mutua de Terrassa
    Terrassa, Spain
  • Hospital Clínico Universitario de Valencia
    Valencia, Spain
  • Hospital General Universitario de Valencia
    Valencia, Spain

Showing the first 100 of 105 sites across 11 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Baselga J, Manikhas A, Cortes J, Llombart A, Roman L, Semiglazov VF, Byakhov M, Lokanatha D, Forenza S, Goldfarb RH, Matera J, Azarnia N, Hudis CA, Rozencweig M. Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol. 2014 Mar;25(3):592-598. doi: 10.1093/annonc/mdt543. Epub 2014 Jan 8. Erratum In: Ann Oncol. 2019 Jun 1;30(6):1017. doi: 10.1093/annonc/mdy529. PubMed 24401928 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 31, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00294996
Lead sponsor
Sopherion Therapeutics
First posted
Feb 22, 2006
Start date
Jan 2006
Last update
Mar 31, 2009

Study contacts

Jose Baselga, M.D.
principal investigator · Vall d'Hebron Hospital, Barcelona, Spain
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion